|Company||Baxter International, Inc.|
|Headquarters||One Baxter Parkway, Deerfield, IL 60015, USA|
|Chairman and CEO||Robert L. Parkinson, Jr.|
|CFO||Robert J. Hombach|
|Founder||Dr. Donald Baxter|
|NYSE stock symbol||BAX|
|Revenue||$16.671 billion (2014)|
|Net income||$2,497 million (2014)|
|Earnings per share||$3.56 USD (2014)|
|Investor relations contact number:||222-948-3371|
Baxter International, Inc. an American health care company, based in Deerfield, Illinois.
The company is involved in the development, manufacturing and marketing of products for patients with infectious diseases, immune disorders, hemophilia, trauma, kidney disease, and other chronic and acute medical conditions.
Its business operations are comprised of two main areas:
BioScience: this segment focuses on immunoglobulin therapies, critical care therapy, pulmonology therapy, regenerative medicine and biosurgery, hemophilia therapy, and vaccines.
Medical Products: this segment represents a little more than half of Baxter’s annual sales. It includes intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics.
It manufactures its products in 30 countries and sells them in over 100 countries.
The company was founded by Donald Baxter in 1931 and incorporated under Delaware law.The business originally manufactured and distributed intravenous therapy solutions.
Baxter International became globally well known after producing the first functioning artificial kidney in 1956.
In 2011 Baxter acquired the medical device company Baxa.
|Income statement data (in $ millions)||2014*||2013*|
|Cost of sales||$8,514||$7,495|
|Marketing and administrative expenses||$4,029||$3,642|
|Research and development expenses||$1,421||$1,165|
|Income before income taxes||$2,439||$2,546|
|Income tax expense||$493||$534|
|Balance sheet data (in $ millions)|
|Long-term debt and lease obligations||$7,606||$8,126|
|Total Baxter International Inc. shareholders’ equity||$8,120||$8,463|
|Common share data (in $)|
|Earnings per Common Share – Basic||$3.59||$3.70|
|Earnings per Common Share – Diluted||$3.56||$3.66|
|Cash flow data (in $ millions)|
|Cash flows from operations||$3,215||$3,198|
|Cash flows from investing activities||$(1,542)||$(5,362)|
|Cash flows from financing activities||$(1,402)||$1,645|
|Cash and equivalents at beginning of period||$2,733||$3,270|
|Cash and equivalents at end of period||$2,925||$2,733|
*Years Ended December 31
Source: “Baxter International, Inc. Form 10-K 2014”